FDA approves pralsetinib for lung cancer with RET gene fusions

02/16/2021 By Dr. Dan Platt

Summary: The Food and Drug Administration (FDA) has granted accelerated approval to Gavreto, the second drug for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).

Dr. Dan’s Takeaway: The RET mutation signals cells to grow uncontrollably and is found in ~2% of NSCLC as well as several forms of thyroid cancer. Gavreto and another drug, Retevmo (approved May 2020), are selective inhibitors of the mutant RET protein and are very effective in patients who have this mutation. Though data is still coming in because these drugs were approved in the middle of clinical trials, the progression free survival for Retevmo is 17.5 months in previously-treated NSCLC. These drugs will immediately become standard of care for the few patients with metastatic NSCLC that contains the RET mutation.

Resources:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions

Deskside with Dr. Dan

“One small way I am personally contributing to education is through sharing my take on academic and industry articles, using my medical background to boil down the jargon and pull out the benefits of the news for you.”

– Dan Platt, M.D.

Chief Medical Officer

About The Poster

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore the latest Hub posts

Programs

Somewhere Before & After: Schrödinger’s Cancer

Ellis defined the space between when you had testing and biopsies done and when you finally get results as Schrödinger’s Cancer. The Gryt Health team is republishing and resharing this piece on August 13, 2022, as we remember and honor Ellis’ life with a Virtual Celebration of Life. Ellis Emerson (1985-2022)

Tell Your Story

Maria Farah’s Story

Breast cancer survivor Maria shares what Gryt Is as a person diagnosed at 28.

Want Email Updates?

Get updates in your inbox when new content is posted on the website.

Find value in this post? Please share!

Share on facebook
Share on linkedin
Share on twitter
Share on email

You are never alone

View our resources for those who are experiencing, have experienced, or are supporting someone who has experienced a medical diagnosis.